Medpace Holdings Inc (NASDAQ:MEDP) – Equities researchers at Jefferies Group boosted their Q4 2017 earnings estimates for shares of Medpace in a report issued on Friday. Jefferies Group analyst D. Windley now forecasts that the company will earn $0.39 per share for the quarter, up from their prior forecast of $0.38. Jefferies Group has a “Hold” rating and a $38.00 price objective on the stock. Jefferies Group also issued estimates for Medpace’s Q1 2018 earnings at $0.42 EPS, Q2 2018 earnings at $0.45 EPS, Q3 2018 earnings at $0.46 EPS, Q4 2018 earnings at $0.46 EPS, FY2018 earnings at $1.78 EPS and FY2019 earnings at $2.05 EPS.

Several other analysts have also recently commented on the stock. BidaskClub upgraded shares of Medpace from a “hold” rating to a “buy” rating in a research note on Thursday, December 14th. Zacks Investment Research upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a research note on Wednesday, December 13th. William Blair cut shares of Medpace from an “outperform” rating to a “market perform” rating in a research note on Wednesday, November 1st. They noted that the move was a valuation call. Robert W. Baird raised their price objective on shares of Medpace from $32.00 to $35.00 and gave the company a “neutral” rating in a research note on Tuesday, October 31st. Finally, KeyCorp reiterated a “hold” rating on shares of Medpace in a research note on Tuesday, October 17th. Seven research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Medpace presently has a consensus rating of “Hold” and an average price target of $36.60.

Shares of Medpace (NASDAQ MEDP) opened at $36.81 on Monday. The company has a quick ratio of 0.68, a current ratio of 0.68 and a debt-to-equity ratio of 0.36. Medpace has a 52 week low of $21.76 and a 52 week high of $39.64. The company has a market cap of $1,380.00 and a PE ratio of 53.35.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, October 30th. The company reported $0.40 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.36 by $0.04. Medpace had a net margin of 6.44% and a return on equity of 10.00%. The company had revenue of $98.68 million during the quarter, compared to analysts’ expectations of $96.84 million. During the same quarter last year, the business earned $0.40 EPS. The business’s revenue was up 4.1% on a year-over-year basis.

Large investors have recently bought and sold shares of the business. First Quadrant L P CA purchased a new position in Medpace during the 3rd quarter valued at about $119,000. Susquehanna International Group LLP purchased a new position in Medpace during the 2nd quarter valued at about $220,000. Rhumbline Advisers increased its holdings in Medpace by 13.3% during the 2nd quarter. Rhumbline Advisers now owns 9,726 shares of the company’s stock valued at $282,000 after acquiring an additional 1,140 shares in the last quarter. GSA Capital Partners LLP purchased a new position in Medpace during the 2nd quarter valued at about $299,000. Finally, Wells Fargo & Company MN increased its holdings in Medpace by 42.8% during the 3rd quarter. Wells Fargo & Company MN now owns 10,354 shares of the company’s stock valued at $330,000 after acquiring an additional 3,104 shares in the last quarter. Hedge funds and other institutional investors own 16.80% of the company’s stock.

In other Medpace news, major shareholder Medpace Limited Partnership sold 4,600,000 shares of the firm’s stock in a transaction dated Tuesday, December 5th. The shares were sold at an average price of $30.16, for a total transaction of $138,736,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 25.80% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/q4-2017-earnings-estimate-for-medpace-holdings-inc-medp-issued-by-jefferies-group/1799735.html.

About Medpace

Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.

Earnings History and Estimates for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with Analyst Ratings Network's FREE daily email newsletter.